News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Icahn Nominates Four for Forest Laboratories, Inc. (FRX) Board in Second Fight


6/20/2012 7:15:24 AM

Investor Carl Icahn nominated four directors to the board of Forest Laboratories Inc. (FRX) in a second proxy fight against the drugmaker. Icahn nominated Eric Ende, president of Ende BioMedical Consulting Group and a former biotechnology analyst at Merrill Lynch; Andrew Fromkin, the former chief executive officer of Clinical Data Inc., acquired last year by Forest; Pierre Legault, president and CEO of Stone Management LLC and a former chief financial officer for OSI Pharmaceuticals Inc.; and Daniel Ninivaggi, president of Icahn Enterprises, according to regulatory filing today.

Read at Bloomberg
Read at Reuters
Read at CBS News
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES